JOHNSON & JOHNSON
JNJ· NYSE· Pharmaceutical Preparations
- Market cap
- –
- P/FCF
- –
- EV/Sales
- –
- FCF margin
- 20.9%
- ROIC, 5 yr avg
- –
- Revenue, 5 yr CAGR
- +2.7%
We record prices for the companies we cover; JNJ is not one of them yet.
Company statistics
Profile · FY2025
- Market cap
- –
- Enterprise value
- –
- Diluted shares
- 2.43B
- Revenue
- $94.2B
- Free cash flow
- $19.7B
- Owner earnings
- $18.3B
Valuation · FY2025
- P/E
- –
- P/FCF
- –
- P/Owner earnings
- –
- EV/Sales
- –
- EV/FCF
- –
- P/B
- –
Margins · FY2025
- Gross
- 67.9%
- Operating
- –
- Net
- 28.5%
- Free cash flow
- 20.9%
- Owner earnings
- 19.5%
- Stock pay
- 1.4%
Returns
- ROIC, FY2025
- –
- ROIC, 5 yr avg
- –
- ROE, FY2025
- 32.9%
- ROE, 5 yr avg
- 31.0%
Growth (CAGR)
- Revenue, 3 yr
- 5.6%
- Revenue, 5 yr
- 2.7%
- Revenue, 9 yr
- 3.0%
- Diluted EPS, 3 yr
- 17.9%
- Diluted EPS, 5 yr
- 14.9%
- Diluted EPS, 9 yr
- 7.1%
- Free cash flow, 3 yr
- 4.7%
- Free cash flow, 5 yr
- -0.5%
- Free cash flow, 9 yr
- 2.7%
Financial health · FY2025
- Cash and investments
- $20.1B
- Total debt
- $49.9B
- Net debt
- $29.8B
- Debt/Equity
- 0.6x
- Debt/FCF
- 2.5x
Shareholder returns · FY2025
- Dividend yield
- –
- Payout ratio
- –
- Buyback yield
- –
- Shareholder yield
- –
- Share count, 5 yr
- -1.9%
Financials: ten years from the 10-Ks
Revenue
$94.2B
+3.0% a year over 9 years
FY2016FY2025
Margins
Gross67.9%Net28.5%
FY2025
FY2016FY2025
Free cash flow and owner earnings
Free cash flow$19.7BOwner earnings$18.3B
Free cash flow +2.7% a year
FY2016FY2025
Diluted shares
2.43B
-12.9% over 9 years, net buybacks
FY2016FY2025
Net debt (below zero)
-$29.8B
$29.8B more debt than cash
FY2016FY2025
Every figure, year by year
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| The business | ||||||||||
| Revenue | $71.9B | $76.5B | $81.6B | $82.1B | $82.6B | $78.7B | $80.0B | $85.2B | $88.8B | $94.2B |
| Revenue growth | – | 6.3% | 6.7% | 0.6% | 0.6% | -4.7% | 1.6% | 6.5% | 4.3% | 6.0% |
| Gross margin | 69.7% | 66.7% | 66.8% | 66.4% | 65.6% | 70.3% | 69.3% | 68.8% | 69.1% | 67.9% |
| Operating margin | – | – | – | – | – | – | – | – | – | – |
| Net income | $16.5B | $1.3B | $15.3B | $15.1B | $14.7B | $20.9B | $17.9B | $35.2B | $14.1B | $26.8B |
| Net margin | 23.0% | 1.7% | 18.8% | 18.4% | 17.8% | 26.5% | 22.4% | 41.3% | 15.8% | 28.5% |
| Diluted EPS | $5.93 | $0.47 | $5.61 | $5.63 | $5.51 | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 |
| Return on invested capital? | – | – | – | – | – | – | – | – | – | – |
| Cash | ||||||||||
| Operating cash flow | $18.8B | $21.1B | $22.2B | $23.4B | $23.5B | $23.4B | $21.2B | $22.8B | $24.3B | $24.5B |
| Capital expenditure | $3.2B | $3.3B | $3.7B | $3.5B | $3.3B | $3.7B | $4.0B | $4.5B | $4.4B | $4.8B |
| Free cash flow | $15.5B | $17.8B | $18.5B | $19.9B | $20.2B | $19.8B | $17.2B | $18.2B | $19.8B | $19.7B |
| Stock-based compensation | $878.0M | $962.0M | $978.0M | $977.0M | $1.0B | $1.1B | $1.1B | $1.2B | $1.2B | $1.4B |
| Owner earnings? | $14.7B | $16.8B | $17.6B | $18.9B | $19.2B | $18.6B | $16.0B | $17.1B | $18.7B | $18.3B |
| Free cash flow per share | $5.57 | $6.48 | $6.79 | $7.42 | $7.56 | $7.39 | $6.45 | $7.13 | $8.17 | $8.11 |
| Capital allocation | ||||||||||
| Dividends paid | – | – | – | – | – | – | – | – | – | – |
| Share repurchases | $9.0B | $6.4B | $5.9B | $6.7B | $3.2B | $3.5B | $6.0B | $5.1B | $2.4B | $6.0B |
| Diluted shares | 2.79B | 2.75B | 2.73B | 2.68B | 2.67B | 2.67B | 2.66B | 2.56B | 2.43B | 2.43B |
| Share count change? | -0.9% | -1.6% | -0.6% | -1.6% | -0.5% | 0.1% | -0.4% | -3.9% | -5.1% | 0.0% |
| Balance sheet | ||||||||||
| Cash and equivalents | $19.0B | $17.8B | $18.1B | $17.3B | $14.0B | $14.5B | $12.9B | $21.9B | $24.1B | $19.7B |
| Short-term investments | $22.9B | $472.0M | $1.6B | $2.0B | $11.2B | $17.1B | $9.4B | $1.1B | $417.0M | $393.0M |
| Total debt | $28.8B | $36.1B | $33.1B | $27.7B | $37.1B | $35.9B | $41.2B | $30.8B | $38.4B | $49.9B |
| Net debt | -$13.1B | $17.8B | $13.4B | $8.4B | $11.9B | $4.3B | $18.9B | $7.9B | $13.9B | $29.8B |
| Shareholders' equity | $70.4B | $60.2B | $59.8B | $59.5B | $63.3B | $74.0B | $76.8B | $68.8B | $71.5B | $81.5B |
Latest filings
| 2026-10-21 | 10-Q | Quarterly report |
| 2026-10-13 | 8-K | Earnings release |
| 2026-07-23 | 10-Q | Quarterly report |
| 2026-07-15 | 8-K | Earnings release |
| 2026-04-22 | 10-Q | Quarterly report |
| 2026-04-14 | 8-K | Earnings release |
| 2026-03-11 | DEF 14A | Proxy statement |
| 2026-02-11 | 10-K | Annual report |
| 2026-01-21 | 8-K | Earnings release |
| 2025-10-22 | 10-Q | Quarterly report |
More from our coverage
- MSFTPlatforms8.4MicrosoftThe most entrenched software franchise in the enterprise, now spending its cash flow on AI capacity; a great business we would own with a margin of safety, not at any price.Base value $410.29
- NVDAAI infrastructure8.4NVIDIAThe best business in technology at the top of its cycle: the moat is CUDA as much as silicon, but today's margins are a peak, not a floor.Base value $104.32
- AAPLHardware7.6AppleOne of the highest-quality businesses in the world growing in the low single digits; the price usually assumes more growth than the numbers show.Base value $134.27
- GOOGLPlatforms7.4AlphabetSearch pays for everything, and AI is both its biggest threat and its biggest opportunity; the price has to allow for search being worth less than it was.Base value $209.60
- NOWSoftware7.4ServiceNowA rare enterprise platform still growing above 20% with high retention; the free cash flow is real but stock pay takes a large share of it.Base value $189.13
- ADBESoftware7.4AdobeSuperb margins and a shrinking share count, priced for decline; the question is whether AI makes Adobe's tools more valuable or makes them unnecessary.Base value $449.35
